Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director · Chief Operating Officer · 10% owner | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of LifeSci Investments, LLC | 1,701,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,701,000 F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 30, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347,085 |
Reported balance
After 2023-10-30 transaction · row 1
1 source rowRow 1 · 2023-10-30 · Sale · Disposed 72,603 · Balance 347,085 F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2022 Filed Mar 10, 2022 02:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001437749-22-005779 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 02:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $23.81 | $238,100.00 |
DisclosureSEC source: 0001437749-22-005779 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,985 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 21, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.64 to $23.96, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 02:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.90 | $19,000.00 |
DisclosureSEC source: 0001437749-22-005779 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 02:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001437749-22-005779 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 02:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $23.80 | $238,000.00 |
DisclosureSEC source: 0001437749-22-005779 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,985 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.57 to $24.14, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 02:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.90 | $19,000.00 |
DisclosureSEC source: 0001437749-22-005779 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 874 | $23.78 | $20,783.72 |
DisclosureSEC source: 0001437749-22-005229 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,891 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 70,094 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-005774 · rdgdoc.xml · derivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,094 Underlying: Common Stock · 70,094 shares Expires not disclosed F3 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F3 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F3 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 70,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-005774 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,859 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation. F2 · balance_after: The amount represented in Column 5 of Table I reflects the amount of securities beneficially owned by the reporting person as of the transaction date reported herein. It does not give effect to the transaction reported by the reporting person on the Form 4 filed by the reporting person on March 3, 2022. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 690 | $29.38 | $20,272.20 |
DisclosureSEC source: 0001437749-22-003343 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,765 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 16,670 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001437749-22-002647 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,670 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 16,670 | $27.84 | $464,092.80 |
DisclosureSEC source: 0001437749-22-002647 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.35 to $28.43, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 16,670 | $1.78 | $29,672.60 |
DisclosureSEC source: 0001437749-22-002647 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 02:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 16,666 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001437749-22-002428 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,670 Underlying: Common Stock · 16,666 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 02:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 16,666 | $29.90 | $498,313.40 |
DisclosureSEC source: 0001437749-22-002428 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 to $30.54, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 02:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 16,666 | $1.78 | $29,665.48 |
DisclosureSEC source: 0001437749-22-002428 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 16,666 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001437749-22-000824 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,336 Underlying: Common Stock · 16,666 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 16,666 | $31.72 | $528,645.52 |
DisclosureSEC source: 0001437749-22-000824 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.17 to $32.19, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 16,666 | $1.78 | $29,665.48 |
DisclosureSEC source: 0001437749-22-000824 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 16,666 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001437749-22-000824 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,002 Underlying: Common Stock · 16,666 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 16,666 | $30.83 | $513,812.78 |
DisclosureSEC source: 0001437749-22-000824 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.67 to $31.53, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 16,666 | $1.78 | $29,665.48 |
DisclosureSEC source: 0001437749-22-000824 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2021 Filed Dec 31, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 928 | $39.37 | $36,535.36 |
DisclosureSEC source: 0001437749-21-029532 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,455 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 16,666 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001437749-21-028681 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,668 Underlying: Common Stock · 16,666 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 16,666 | $32.80 | $546,644.80 |
DisclosureSEC source: 0001437749-21-028681 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $33.71, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 16,666 | $1.78 | $29,665.48 |
DisclosureSEC source: 0001437749-21-028681 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 16,666 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001437749-21-028681 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 16,666 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 16,666 | $33.82 | $563,644.12 |
DisclosureSEC source: 0001437749-21-028681 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $34.51, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 16,666 | $1.78 | $29,665.48 |
DisclosureSEC source: 0001437749-21-028681 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,464 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-028267 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,464 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,464 | $35.15 | $402,959.60 |
DisclosureSEC source: 0001437749-21-028267 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.96 to $35.46, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,464 | $1.64 | $18,800.96 |
DisclosureSEC source: 0001437749-21-028267 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-028267 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,464 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $36.52 | $418,555.72 |
DisclosureSEC source: 0001437749-21-028267 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $37.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-028267 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 3, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 957 | $37.59 | $35,973.63 |
DisclosureSEC source: 0001437749-21-027750 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,383 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-025355 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,925 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $56.81 | $651,099.41 |
DisclosureSEC source: 0001437749-21-025355 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,340 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.46 to $58.15, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-025355 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 5, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-025355 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,386 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| November 02, 2021 Filed Nov 5, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $54.72 | $627,145.92 |
DisclosureSEC source: 0001437749-21-025355 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,340 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.78 to $55.96, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 02, 2021 Filed Nov 5, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-025355 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,215 | $39.97 | $128,503.55 |
DisclosureSEC source: 0001437749-21-023857 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,340 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 01:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-023466 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,847 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 01:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $40.55 | $464,743.55 |
DisclosureSEC source: 0001437749-21-023466 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,555 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.81 to $40.92, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 01:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-023466 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 01:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-023466 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,308 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 01:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $40.63 | $465,660.43 |
DisclosureSEC source: 0001437749-21-023466 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,555 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $41.08, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 01:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-023466 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2021 Filed Oct 1, 2021 00:17 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 907 | $43.12 | $39,109.84 |
DisclosureSEC source: 0001437749-21-022968 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,555 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.